Johnson & Johnson (JNJ DU) stock market data APIs
€176.7088
0.52(0.3%)
as of December 30, 2025
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.DU.
Prev. Close
176.7088
Open
177.4935
High
177.9633
Low
175.9939
52 wk Range
127.2657-182.76
Market Cap
385 769 M
Dividends (Yield)
0.0222
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026
NEW BRUNSWICK, N.J., January 02, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 pe...
Here’s What Analysts Think About Halozyme Therapeutics (HALO)
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Jo...
AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shar...
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
This article first appeared on GuruFocus. Pfizer (PFE, Financials) and GSK (GSK, Financials) are leading a new round of price adjustments set to take effect in early 2026, with data from healthcare a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
